TENAYA and LUCERNE
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
PURPOSE: To evaluate 2-year efficacy, durability, and safety of the bispecific antibody faricimab, which inhibits both angiopoietin-2 and VEGF-A. DESIGN: TENAYA (ClinicalTrials.gov identifier, NCT03823287) and LUCERNE (ClinicalTrials.gov identifier, NCT03823300) were identically designed, randomized, double-masked, active comparator-controlled phase 3 noninferiority trials. PARTICIPANTS: Treatment-naive patients with neovascular age-related macular degeneration (nAMD) 50 years of age or older. METHODS: Patients were randomized (1:1) to intravitreal faricimab 6.0 mg up to every 16 weeks (Q16W) or aflibercept 2.0 mg every 8 weeks (Q8W). Faricimab fixed dosing based on protocol-defined disease activity at weeks 20 and 24 up to week 60, followed up to week 108 by a treat-and-extend personalized treatment interval regimen. MAIN OUTCOME MEASURES: Efficacy analyses included change in best-corrected visual acuity (BCVA) from baseline at 2 years (averaged over weeks 104, 108, and 112) and proportion of patients receiving Q16W, every 12 weeks (Q12W), and Q8W dosing at week 112 in the intention-to-treat population. Safety analyses included ocular adverse events (AEs) in the study eye through study end at week 112. RESULTS: Of 1326 patients treated across TENAYA/LUCERNE, 1113 (83.9%) completed treatment (n = 555 faricimab; n = 558 aflibercept). The BCVA change from baseline at 2 years was comparable between faricimab and aflibercept groups in TENAYA (adjusted mean change, +3.7 letters [95% confidence interval (CI), +2.1 to +5.4] and +3.3 letters [95% CI, +1.7 to +4.9], respectively; mean difference, +0.4 letters [95% CI, -1.9 to +2.8]) and LUCERNE (adjusted mean change, +5.0 letters [95% CI, +3.4 to +6.6] and +5.2 letters [95% CI, +3.6 to +6.8], respectively; mean difference, -0.2 letters [95% CI, -2.4 to +2.1]). At week 112 in TENAYA and LUCERNE, 59.0% and 66.9%, respectively, achieved Q16W faricimab dosing, increasing from year 1, and 74.1% and 81.2%, achieved Q12W or longer dosing. Ocular AEs in the study eye were comparable between faricimab and aflibercept groups in TENAYA (55.0% and 56.5% of patients, respectively) and LUCERNE (52.9% and 47.5% of patients, respectively) through week 112. CONCLUSIONS: Treat-and-extend faricimab treatment based on nAMD disease activity maintained vision gains through year 2, with most patients achieving extended dosing intervals. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Self-citationRanibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., Kim, R. Y., Sy, J. P., & Schneider, S. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062655 · Cited by 3,522
Self-citationIntravitreal Aflibercept Injection for Neovascular Age-related Macular Degeneration
Schmidt-Erfurth, U., Kaiser, P. K., Korobelnik, J.-F., Brown, D. M., Chong, V., Nguyen, Q. D., Ho, A. C., Ogura, Y., Simader, C., Jaffe, G. J., et al. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2013.08.011 · Cited by 822
Self-citationHeier, J. S., Khanani, A. M., Quezada Ruiz, C., Basu, K., Ferrone, P. J., Brittain, C., Figueroa, M. S., Lin, H., Holz, F. G., Patel, V., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00010-1 · Cited by 785
Self-citationTherapeutic targeting of the angiopoietin–TIE pathway
Saharinen, P., Eklund, L., & Alitalo, K. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.278 · Cited by 620
Swaroop, A., Chew, E. Y., Bowes Rickman, C., & Abecasis, G. R. (2009) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev.genom.9.081307.164350 · Cited by 270
Long-term outcomes of treatment of neovascular age-related macular degeneration
Gillies, M. C., Campain, A., Barthelmes, D., Simpson, J. M., Arnold, J. J., Guymer, R. H., McAllister, I. L., Essex, R. W., Morlet, N., & Hunyor, A. P. (2015) · Ophthalmology · doi:10.1016/j.ophtha.2015.05.010 · Cited by 254
Self-citationMitchell, P., Holz, F. G., Hykin, P., Midena, E., Souied, E., Allmeier, H., Lambrou, G., Schmelter, T., Wolf, S., & on behalf of the ARIES study investigators (2021) · Retina · doi:10.1097/iae.0000000000003128 · Cited by 101
Self-citationCohen, S. Y., Oubraham, H., Uzzan, J., Dubois, L., & Tadayoni, R. (2012) · Retina · doi:10.1097/iae.0b013e318240a516 · Cited by 61
Self-citation
Metadata
- Authors
- Khanani, A. M., Kotecha, A., Chang, A., Chen, S.-J., Chen, Y., Guymer, R., Heier, J. S., Holz, F. G., Iida, T., Ives, J. A., Lim, J. I., Lin, H., Michels, S., Quezada Ruiz, C., Schmidt-Erfurth, U., Silverman, D., Singh, R., Swaminathan, B., Willis, J. R., Tadayoni, R., Abbey, A., Abdulaeva, E., Abraham, P., Adan Civera, A., Agostini, H., Alezzandrini, A., Alfaro, V., Almony, A., Altay, L., Amini, P., Antoszyk, A., Aradi, E., Arias, L., Arnold, J., Asaria, R., Astakhov, S., Astakhov, Y., Awh, C. C., Balaratnasingam, C., Banerjee, S., Baumal, C., Becker, M., Belfort, R., Bratko, G., Bridges, W. Z., Brown, J., Brown, D. M., Budzinskaya, M., Buffet, S., Burgess, S., Byon, I., Cagini, C., Calzada, J., Cameron, S., Campochiaro, P., Carlson, J., Carneiro, A., Chan, C., Chang, E., Chang, A., Chao, D., Chaudhry, N., Chee, C., Cheek, A., Chen, S.-J., Chen, S.-N., Cheung, G., Chexal, S., Chittum, M., Chow, D., Cole, A., Connolly, B., Cornut, P. L., Couvillion, S., Danzig, C., Daskalov, V., Dessouki, A., Devin, F., Dollin, M., Dolz, R., Downey, L., Dreyer, R., Dugel, P., Eichenbaum, D., Eldem, B., Engstrom, R., Escobar, J. J., Eter, N., Faber, D. W., Falk, N., Feiner, L., Vega, A. F., Ferrone, P., Figueroa, M., Fine, H., Fineman, M., Fox, G. M., Francais, C., Franco, P., Fraser-Bell, S., Fung, N., Sola, F. F., Gale, R., Garcia-Layana, A., Gasperini, J., Gawecki, M., Ghanchi, F., Gill, M., Giunta, M., Glaser, D., Goldstein, M., Ulla, F. G., Gomi, F., Gonzalez, V., Graff, J., Gupta, S., Guthoff, R., Guymer, R., Haas, A., Hampton, R., Hatz, K., Hayashi, K., Heier, J., Herba, E., Hershberger, V., Higgins, P., Holekamp, N., Honda, S., Howard, J., Hu, A., Huddleston, S., Iida, T., Imaizumi, H., Ito, Y., Ito, Y., Itty, S., Javey, G., Javid, C., Kaga, T., Kaluzny, J., Kang, S. W., Kapoor, K., Karabas, L., Kawasaki, T., Kelty, P., Kerenyi, A., Khanani, A., Khoramnia, R., Khurana, R., Kimura, K., Klein-Mascia, K., Kobayashi, N., Kodjikian, L., Koizumi, H., Kokame, G., Kulikov, A., Kwong, H., Kwun, R., Lai, T., Lai, C.-C., Lalonde, L., Lanzetta, P., Larsen, M., Lavina, A., Lee, W. K., Lee, J. E., Lee, S., Levy, J., Lindsell, L., Liu, M., London, N., Lotery, A., Lozano Rechy, D., Luckie, A., Maberley, D., Maeno, T., Mahmood, S., Makkouk, F., Marcus, D., Margherio, A., Masse, H., Matsubara, H., Maturi, R., Mehta, S., Menon, G., Mentes, J., Michels, M., Mitamura, Y., Mitchell, P., Mohamed, Q., Mones, J., Lobo, R. M., Montero, J., Moore, J., Mori, R., Morori-Katz, H., Mukherjee, R., Murata, T., Muzyka-Wozniak, M., Nardi, M., Narendran, N., Nicolo, M., Nielsen, J., Nishimura, T., Noda, K., Nowinska, A., Oh, H., Ohr, M., Okada, A., Oleksy, P., Ono, S., Ozdek, S., Ozturk, B., Pablo, L., Park, K. H., Parke, D. W., Parravano, M. C., Patel, P., Patel, A., Patel, S., Patel, S., Pauleikhoff, D., Pearce, I., Pearlman, J., Petkova, I., Pieramici, D., Pozdeyeva, N., Qureshi, J., Raczynska, D., Ramirez Estudillo, J., Rathod, R., Razavi, H., Regillo, C., Reilly, G., Ricci, F., Rich, R., Romanowska-Dixon, B., Rosenblatt, I., Ruiz Moreno, J. M., Sacu, S., Saedon, H., Saeed, U., Sagong, M., Sakamoto, T., Sandhu, S., Sararols, L., Saravia, M., Schadlu, R., Schlottmann, P., Sekiryu, T., Seres, A., Sermet, F., Shah, S., Shah, R., Shah, A., Sheidow, T., Sheth, V., Shiragami, C., Sikorski, B., Silva, R., Singerman, L., Sisk, R., Sørensen, T. L., Souied, E., Spinak, D.-J., Staurenghi, G., Steinmetz, R., Stoller, G., Stoltz, R., Suan, E., Suner, I., Yzer, S., Tadayoni, R., Takahashi, K., Takayama, K., Taleb, A., Talks, J., Terasaki, H., Thompson, J., Toth-Molnar, E., Tran, K., Tuli, R., Uchiyama, E., Vajas, A., Lith-Verhoeven, J. V., Varsanyi, B., Viola, F., Virgili, G., Vogt, G., Völker, M., Warrow, D., Weber, P., Wells, J. A., Wickremasinghe, S., Wieland, M., Williams, G., Williams, T., Wong, D., Wong, K., Wong, J., Wong, I., Wong, R., Wowra, B., Wykoff, C. C., Yamashita, A., Yasuda, K., Yilmaz, G., Yiu, G., Yoneda, A., Yoon, Y. H., Yoreh, B., Yu, H. G., Yu, S. Y., Yurieva, T., Zambrano, A., Zatorska, B., & Zeolite, C.
- Venue
- Ophthalmology
- Publisher
- Elsevier BV
- Published
- 2024-08
- Volume
- 131
- Issue
- 8
- Pages
- 914-926
- ISSN
- 0161-6420 (ISSN-L)
- OpenAlex
- W4391930651
- Cited by
- 227
- References
- 9
- FWCI
- 77.15
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: TENAYA and LUCERNE. https://app.cochat.ai/papers/10.1016/j.ophtha.2024.02.014
- The paper
- Khanani, A. M., Kotecha, A., Chang, A., Chen, S.-J., Chen, Y., Guymer, R., Heier, J. S., Holz, F. G., Iida, T., Ives, J. A., Lim, J. I., Lin, H., Michels, S., Quezada Ruiz, C., Schmidt-Erfurth, U., Silverman, D., Singh, R., Swaminathan, B., Willis, J. R., . . . Zeolite, C. (2024). TENAYA and LUCERNE. Ophthalmology. https://doi.org/10.1016/j.ophtha.2024.02.014
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.